Increase in 39-week induction rate, reduction in rate of cesarean delivery observed after publication of trial in August 2018<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 11, 2023 (HealthDay News) — An increase in 39-week induction rates and a decrease in cesarean delivery (CD) rates were seen following publication of A Randomized Trial of Induction vs Expectant Management (ARRIVE) in August 2018, according to a research letter published online Aug. 10 in JAMA Network Open<\/em>.<\/p>\n Rachel Wood, M.D., from Brigham and Women’s Hospital in Boston, and colleagues examined whether publication of the ARRIVE trial in August 2018, which revealed that low-risk nulliparous patients who were induced at 39 weeks of gestation had a reduced risk for CD, was associated with observable obstetric practice changes in the United States. Data were obtained for 2,860,942 births (66 and 34 percent from the pre-ARRIVE and post-ARRIVE periods, respectively).<\/p>\n The researchers observed an immediate increase in 39-week induction rates after the dissemination period, with a 39-week induction rate of 15.0 percent compared with an expected 13.8 percent based on trends during the pre-ARRIVE period (adjusted incident rate ratio [aIRR], 1.10); CD rates were significantly lower than expected (24.7 versus 25.1 percent; aIRR, 0.988). Significant ongoing temporal changes included an increase of 0.009 39-week inductions and a decrease of 0.0014 CDs per month.<\/p>\n “These findings suggest that the publication of the ARRIVE trial was associated with an increase in 39-week induction rates and a reduction in CD rates for low-risk nulliparous patients across the United States,” the authors write.<\/p>\n Several authors disclosed ties to the biomedical and medical technology industries.<\/p>\n